Document is current
Any future updates will be listed below
-
Authors
Ando, Chihiro
Ichihara, Eiki
Yokoyama, Toshihide
Inoue, Koji
Tamura, Tomoki
Fujiwara, Keiichi
Oda, Naohiro
Kano, Hirohisa
Kishino, Daizo
Watanabe, Kazuhiko
Inoue, Masaaki
Ochi, Nobuaki
Onishi, Fumie
Ichikawa, Hirohisa
Kobe, Hiroshi
Tachibana, Sayaka
Hotta, Katsuyuki
Maeda, Yoshinobu
Kiura, Katsuyuki
- License Information
-
More Information
Article History
Received: 22 July 2022
Accepted: 11 October 2022
First Online: 29 October 2022
Declarations
:
: Eiki Ichihara received honoraria from AstraZeneca K.K., Novartis, Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer, Bristol-Myers Squibb Co. Ltd., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Boehringer Ingelheim. Eiki Ichihara received research funding from Janssen Pharmaceutical K.K., Pfizer, Bristol-Myers Squibb Co. Ltd., Ono Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd. Toshihide Yokoyama received honoraria from AstraZeneca K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc, Bristol-Myers Squibb Co. Ltd., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Nippon Kayaku Co., Ltd., Boehringer Ingelheim Japan Inc. Toshihide Yokoyama also recieved research funding from MSD, Takeda Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co. Ltd., Boehringer Ingelheim Japan Inc. Koji Inoue received honoraria from AstraZeneca, Takeda, Shionogi, Kyowa Kirin, Ono, Towa, Chugai and Boehringer ingelheim. Tomoki Tamura received honoraria from Chugai Pharmaceutical Co., Ltd, and Taiho Pharmaceutical Co., Ltd. Keiichi Fujiwara received honoraria from MSD, AstraZeneca, Ono Pharmaceutical Co., Sanofi, and Eli Lilly Japan. Hirohisa Kano received honoraria from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb and ONO Pharmaceutical. Masaaki Inoue received honoraria from Bristol Myers Squibb, Chugai Pharmaceutical Co, Daiichi-Sankyo, Kyowa Kirin Co, AstraZeneca and Taiho Pharmaceutical Co. Hiroshi Kobe received honoraria from Boehringer ingelheim and Chugai pharmaceutical. Katsuyuki Hotta received honoraria from MSD, AstraZeneca, Chugai pharmaceutical, Lilly, BMS and Abbvie. He also received research funding from Pfizer, AstarZeneca, Chugai pharmaceutical, Lilly, Takeda Pharmaceutical, MSD, BMS, Ono pharmaceutical, Taiho pharmaceutical and Boehringer ingelheim. Yoshinobu Maeda received honoraria from AstraZeneca K.K., Amgen K.K., ONO pharmaceutical co., LTD., Bristol-Myers Squibb K.K., Takeda Pharmaceutical ltd., Chugai Pharmaceutical Co.,Ltd., Novartis, Pfizer Japan Inc., and Janssen Pharmaceutical K.K. Yoshinobu Maeda also received reserch funding from Chugai Pharmaceutical Co.,Ltd., AstraZeneca K.K., Novartis and Janssen Pharmaceutical K.K. Katsuyuki Kiura received honoraria from AstraZeneca, Novartis, Lilly, Taiho Pharmaceutical Co. td., Chugai Pharmaceutical, Pfizer, Ono pharmaceutical, MSD, BMS, Boehringer ingelheim, Daiichi Sankyo, Takeda and Nippon Kayaku. He also received research funding from Merk BioPharma, Kyowa Kirin, Pfizer, MSD, Boehringer ingelheim, Shionogi pharmaceutical, and Ono pharmaceutical.
